Skip to Main Content

Yuefan guides clients through complex corporate transactions, with a focus on the cannabis sector.

Yuefan has experience representing large corporations, multinational companies and investors in complex commercial agreements, mergers and acquisitions, joint ventures, share and purchase agreements, and equity financings in both the U.S. and China. Having worked extensively in the agribusiness, life sciences and energy industries, he currently focuses his practice on cannabis and industrial hemp. Clients appreciate his guidance through this ever-changing regulatory environment and the unprecedented opportunities of today’s market landscape.

Yuefan especially enjoys the intricacies of drafting complicated deal documents tailored to the particular business transaction envisioned by the client. He is known for his communication skills: both listening to client business goals and making it a priority to ensure that clients understand the legal issues at stake. He aims to draft agreements that meet each client’s unique business needs and circumstances, rather than offering one-size-fits-all answers. It’s a skill he honed during his stint practicing U.S. corporate law in Beijing and Shanghai, where clients often required highly customized transactions.




  • J.D., University of Texas School of Law
    • with honors
  • B.A., Vanderbilt University
    • magna cum laude
    • Psychology major, mathematics minor


  • Colorado
  • District of Columbia


  • Mandarin, fluent
  • Shanghainese, fluent

*Contact Yuefan to set up an in-person consultation by appointment in the Denver office.

Life Sciences

  • Represented major U.S. pharmaceutical company in spin-off of certain drug businesses, comprising physical assets, intellectual property (IP) and government licenses and approvals, to Chinese pharmaceutical distributor.
  • Represented major U.S. medical devices manufacturer in its acquisition of factory from Chinese medical devices manufacturer.
  • Represented Taiwanese healthcare investment fund in transaction with pioneering U.S. genomics company involving investment in U.S. parent company, along with creation of joint venture in Asia.


  • Represented special committee of Chinese software and mobile applications company in de-listing and going private transaction.
  • Represented management buyers in de-listing and going private of Chinese mobile games company.

Private Equity and Private M&A

  • Represented Hong Kong fund of major U.S. private equity firm in its bid for major business-to-business media company.
  • Represented Chinese-German private equity fund in acquisition of U.S. pharmaceutical company from major U.S. private equity fund.
  • Represented electronics manufacturer partially owned by Beijing municipal government in acquisition of U.S. semiconductor company. Assisted in Committee on Foreign Investment in the United States (CFIUS) filing for transaction, which resulted in rare approval for Chinese acquirer.
  • Represented Rosneft in its CFIUS filing with respect to the acquisition of certain energy assets from Morgan Stanley.

Securities Filings

  • Responsible for U.S. Securities and Exchange Commission (SEC) filings for major Chinese investment fund's investment in Chinese automotive services company. Advised client on SEC rules and prepared filings.
  • Prepared SEC filings in relation to various public mergers, including Form 8-K/6-K, proxy statements and Schedule 13E-3, and Schedule 13D.
Outside the Office

After three years working abroad in China, Yuefan is excited about Denver’s skiing scene. He also enjoys swimming and reading nonfiction, especially history and psychology.

Stay updated.

Subscribe to receive Husch Blackwell’s news and insights.

Select your preferences